Retatrutide

A triple-agonist peptide studied in metabolic research for its simultaneous activity at GLP-1, GIP, and glucagon receptors. Earlier incretin peptides act on a single pathway; retatrutide’s three-receptor profile is why it has become a focus of current research into appetite signalling, nutrient metabolism, and energy expenditure.

• Triple agonist: GLP-1 / GIP / glucagon

• Research context: metabolic and appetite signalling studies

• Batch-specific COA available

• In-vitro laboratory research use only

Not for human or animal consumption, application, injection, clinical, veterinary, or diagnostic use. Supplied to qualified researchers only.